Paull KD - Search Results

1

Development of human tumor cell line panels for use in disease-oriented drug screening.

Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, Boyd MR. Shoemaker RH, et al. Among authors: paull kd. Prog Clin Biol Res. 1988;276:265-86. Prog Clin Biol Res. 1988. PMID: 3051021 Review. No abstract available.

2

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al. Wu L, et al. Among authors: paull kd. Cancer Res. 1992 Jun 1;52(11):3029-34. Cancer Res. 1992. PMID: 1350507

3

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Rubinstein LV, et al. Among authors: paull kd. J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8. doi: 10.1093/jnci/82.13.1113. J Natl Cancer Inst. 1990. PMID: 2359137

4

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. Paull KD, et al. J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92. doi: 10.1093/jnci/81.14.1088. J Natl Cancer Inst. 1989. PMID: 2738938

5

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Scudiero DA, et al. Among authors: paull kd. Cancer Res. 1988 Sep 1;48(17):4827-33. Cancer Res. 1988. PMID: 3409223

6

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Monks A, et al. J Natl Cancer Inst. 1991 Jun 5;83(11):757-66. doi: 10.1093/jnci/83.11.757. J Natl Cancer Inst. 1991. PMID: 2041050

7

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. Monks A, et al. Among authors: paull kd. Anticancer Drug Des. 1997 Oct;12(7):533-41. Anticancer Drug Des. 1997. PMID: 9365500 Review. No abstract available.

8

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.

Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T. Alvarez M, et al. J Clin Invest. 1995 May;95(5):2205-14. doi: 10.1172/JCI117910. J Clin Invest. 1995. PMID: 7738186 Free PMC article.

9

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. Lee JS, et al. Mol Pharmacol. 1994 Oct;46(4):627-38. Mol Pharmacol. 1994. PMID: 7969041

10

Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.

Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y. Solary E, et al. Among authors: paull kd. Biochem Pharmacol. 1993 Jun 22;45(12):2449-56. doi: 10.1016/0006-2952(93)90226-m. Biochem Pharmacol. 1993. PMID: 8392342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters